APA (7th ed.) Citation

Tu, Y., Hanze, E., Zhu, F., Lagraauw, H. M., Sloss, C. M., Method, M., . . . Berkenblit, A. (2024). Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite. British Journal of Clinical Pharmacology, 90(2), 568. https://doi.org/10.1111/bcp.15937

Chicago Style (17th ed.) Citation

Tu, Ya‐Ping, Eva Hanze, Fengying Zhu, H. Maxime Lagraauw, Callum M. Sloss, Michael Method, Brooke Esteves, Eric H. Westin, and Anna Berkenblit. "Population Pharmacokinetics of Mirvetuximab Soravtansine in Patients with Folate Receptor‐α Positive Ovarian Cancer: The Antibody–drug Conjugate, Payload and Metabolite." British Journal of Clinical Pharmacology 90, no. 2 (2024): 568. https://doi.org/10.1111/bcp.15937.

MLA (9th ed.) Citation

Tu, Ya‐Ping, et al. "Population Pharmacokinetics of Mirvetuximab Soravtansine in Patients with Folate Receptor‐α Positive Ovarian Cancer: The Antibody–drug Conjugate, Payload and Metabolite." British Journal of Clinical Pharmacology, vol. 90, no. 2, 2024, p. 568, https://doi.org/10.1111/bcp.15937.